Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 10/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | PAM | P19021 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258563 | 0.98 | GPR84 (0.46) | GPR84FFAR1PAMFFAR4PRSS1 | |
| SCHEMBL10483867 | 0.91 | PLA2G2C (0.44) | GPR84FFAR1PAMFFAR4LMNA | |
| SCHEMBL5261483 | 0.85 | CYP3A4 (0.54) | PRSS1PRSS2PRSS3LMNATSHR | |
| SCHEMBL9629135 | 0.84 | GPR84 (0.59) | GPR84FFAR1PAMFFAR4 | |
| SCHEMBL9629741 | 0.84 | GPR84 (0.59) | GPR84FFAR1PAMFFAR4 | |
| SCHEMBL9628865 | 0.84 | GPR84 (0.59) | GPR84FFAR1PAMFFAR4 | |
| SCHEMBL6561865 | 0.84 | GPR84 (0.59) | GPR84FFAR1PAMFFAR4 | |
| SCHEMBL22160886 | 0.82 | GPR84 (0.49) | GPR84FFAR1PRSS1PRSS2PRSS3 | |
| SCHEMBL10483871 | 0.80 | GPR84 (0.42) | GPR84FFAR1PAMFFAR4PRSS1 | |
| SCHEMBL8214160 | 0.80 | FFAR4 (0.57) | GPR84FFAR1FFAR4PPARDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786381-B1 | ANTI-BACTERIAL COMPOUNDS | BEIERSDORF AG (DE) | 2014-12-03 | — | — | EP | claimed |
| US-20240115511-A1 | NANOMATERIALS COMPRISING AN IONIZABLE LIPID | BEAM THERAPEUTICS INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4281064-A1 | NANOMATERIALS COMPRISING AN IONIZABLE LIPID | Beam Therapeutics Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-116963729-A | Nanomaterial comprising ionizable lipids | 比姆医疗股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022159475-A1 | NANOMATERIALS COMPRISING AN IONIZABLE LIPID | BEAM THERAPEUTICS INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-1786381-B1 | ANTI-BACTERIAL COMPOUNDS | BEIERSDORF AG (DE) | 2014-12-03 | — | — | EP | disclosed |
| US-7335466-B2 | Silver salt photothermographic dry imaging material, image recording method and image forming method for the same | KONICA MINOLTA HOLDINGS, INC. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-20070276045-A1 | Anti-Bacterial Compounds | GIVAUDAN S.A. (CH) | 2007-11-29 | — | — | US | disclosed |
| US-20070276045-A1 | Anti-Bacterial Compounds | GIVAUDAN S.A. (CH) | 2007-11-29 | — | — | US | disclosed |
| US-20070276045-A1 | Anti-Bacterial Compounds | GIVAUDAN S.A. (CH) | 2007-11-29 | — | — | US | disclosed |
| EP-1786381-A1 | ANTI-BACTERIAL COMPOUNDS | Givaudan SA (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006026875-A1 | ANTI-BACTERIAL COMPOUNDS | GIVAUDAN SA (CH) | 2006-03-16 | — | — | WO | disclosed |
| US-4811788-A | ETHOXYLATED SODIUM SULFONATES | THE STANDARD OIL COMPANY (US) | 1989-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276045-A1 | Anti-Bacterial Compounds | SPOUT1, FASN, CYP8B1 | GPR84 2144/4885FFAR1 231/4885PAM 240/4885 |
| US-20240115511-A1 | NANOMATERIALS COMPRISING AN IONIZABLE LIPID | LIPA, SGMS2, PHOSPHO1 | GPR84 4025/4885FFAR1 906/4885PAM 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.